Shares of Verona Pharma plc (NASDAQ:VRNA – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the […]
Verona Pharma plc (NASDAQ:VRNA – Get Free Report) CEO David Zaccardelli sold 8,616 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $2.47, for a total value of $21,281.52. Following the completion of the transaction, the chief executive officer now owns […]
NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to.
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Admin.